Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239182 | 0.91 | GPR119 (0.63) | GPR119LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15749513 | 0.85 | GPR119 (0.56) | GPR119LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3580642 | 0.84 | GPR119 (0.57) | GPR119HRH3 | |
| SCHEMBL5272983 | 0.84 | GPR119 (0.55) | GPR119LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5269797 | 0.83 | HRH3 (0.62) | GPR119LMNAMAPTALDH1A1HRH3 | |
| SCHEMBL23410150 | 0.83 | GPR119 (0.61) | GPR119LMNASMN1; SMN2 | |
| SCHEMBL3577920 | 0.82 | HRH3 (0.56) | LMNAALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL4670351 | 0.82 | HRH3 (0.53) | GPR119HRH3 | |
| SCHEMBL5203383 | 0.82 | HRH3 (0.67) | MAPTALDH1A1HRH3 | |
| SCHEMBL20305696 | 0.81 | MAPT (0.56) | GPR119LMNAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| EP-1567511-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004035556-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | GPR119 338/4885LMNA 4344/4885MAPT 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.